biote Corp. BTMD
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -57.31%
- 1 year
- -60.07%
- Open
- 1.17
- Prev close
- 1.17
- Mkt cap
- 37.63M
- Vol
- 65.59K
- Avg vol
- 204.64K
- EPS
- 0.14
- P/E
- 7.93
- Div yield
- 0.00%
More statistics
- Low
- 1.11
- High
- 1.20
- Forward P/E
- 9.98
- Beta
- 0.00
- Short ratio
- 3.73
- Inst. own
- 64.60%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 5.88
- 200-d avg
- 6.21
- 1y target
- 9.95
News
1 week ago defenseworld.net
Head-To-Head Survey: The Pennant Group (NASDAQ:PNTG) vs. biote (NASDAQ:BTMD)
biote (NASDAQ: BTMD - Get Free Report) and The Pennant Group (NASDAQ: PNTG - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
1 week ago businesswire.com
Biote Schedules Third Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…
3 weeks ago defenseworld.net
biote (NASDAQ:BTMD) and Elevance Health (NYSE:ELV) Head to Head Review
Elevance Health (NYSE: ELV - Get Free Report) and biote (NASDAQ: BTMD - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
-
2 months ago benzinga.com
B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $1.5
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $2 to $1.5.
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
2 months ago seekingalpha.com
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
biote Corp. (BTMD) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
biote Corp. (BTMD) Reports Break-Even Earnings for Q2
biote Corp. (BTMD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.1 per share a year ago.
2 months ago marketbeat.com
biote Q2 Earnings Call Highlights
biote NASDAQ: BTMD reported lower second-quarter revenue and a net loss as a voluntary recall of certain hormone pellets supplied by Asteria Health disrupted procedure volumes, while management said…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
-
2 months ago benzinga.com
Biote Q2 EPS $(0.23) Misses $0.04 Estimate, Sales $44.232M Miss $46.148M Estimate
Biote (NASDAQ:BTMD) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $0.04 by 675 percent. This is a 330 percent decrease over earnings of $0.10 per share…
2 months ago businesswire.com
Biote Reports Second Quarter 2026 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
3 months ago businesswire.com
Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…
5 months ago businesswire.com
Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer
IRVING, Texas--(BUSINESS WIRE)--Biote Corp. (NASDAQ: BTMD) (“Biote” or the “Company”) today announced the appointment of Komal Bajaj, MD, MS, as Chief Medical Officer, effective June 1, 2026. Dr.…
5 months ago gurufocus.com
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
[url="]Biote[/url] (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' pa
-
5 months ago benzinga.com
Biote Reaffirms FY26 Guidance For Revenue Above $190M And Adjusted EBITDA Above $38M
Biote reaffirmed its full year 2026 guidance for revenue above $190 million, Adjusted EBITDA above $38 million, and a return to procedure revenue growth in the second half of this year.
-
5 months ago benzinga.com
Biote Appoints CFO And Chief Business Officer Bob Peterson As Interim CEO And Director, Effective June 8; Bret Christensen Steps Down As CEO
Biote (NASDAQ:BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today announced that Bob Peterson, Chief…
5 months ago businesswire.com
Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
5 months ago seekingalpha.com
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
biote Corp. (BTMD) Q1 2026 Earnings Call Transcript
5 months ago zacks.com
biote Corp. (BTMD) Q1 Earnings and Revenues Lag Estimates
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, missing the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.08 per share a year ago.
-
5 months ago benzinga.com
Biote Q1 2026 Earnings Call: Complete Transcript
Biote Q1 2026 Earnings Call: Complete Transcript
-
5 months ago benzinga.com
Biote Q1 EPS $0.06 Beats $0.03 Estimate, Sales $44.935M Miss $46.023M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.03 by 100 percent. This is a 83.78 percent decrease over earnings of $0.37 per share…
5 months ago businesswire.com
Biote Reports First Quarter 2026 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
6 months ago businesswire.com
Biote Schedules First Quarter 2026 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our…
-
6 months ago benzinga.com
Truist Securities Maintains Buy on Biote, Lowers Price Target to $4
Truist Securities analyst Gregory Fraser maintains Biote (NASDAQ:BTMD) with a Buy and lowers the price target from $5 to $4.
-
7 months ago benzinga.com
B. Riley Securities Maintains Neutral on Biote, Lowers Price Target to $2
B. Riley Securities analyst Jeff Van Sinderen maintains Biote (NASDAQ:BTMD) with a Neutral and lowers the price target from $3 to $2.
7 months ago seekingalpha.com
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
biote Corp. (BTMD) Q4 2025 Earnings Call Transcript
7 months ago zacks.com
biote Corp. (BTMD) Q4 Earnings and Revenues Top Estimates
biote Corp. (BTMD) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.1 per share a year ago.
-
7 months ago benzinga.com
Biote Q4 EPS $0.06 Beats $0.05 Estimate, Sales $46.408M Beat $46.190M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 40 percent decrease over earnings of $0.10 per share…
7 months ago businesswire.com
Biote Reports Fourth Quarter and Full Year 2025 Financial Results
IRVING, Texas--(BUSINESS WIRE)--Biote (NASDAQ: BTMD), a leader in innovative hormone optimization and healthy aging solutions that advance the healthspan of our practitioners' patients, today…
-
7 months ago benzinga.com
Earnings Scheduled For March 11, 2026
Earnings Scheduled For March 11, 2026
8 months ago businesswire.com
Biote Schedules Fourth Quarter and Full Year 2025 Financial Results Release and Conference Call
IRVING, Texas--(BUSINESS WIRE)--biote Corp. (Nasdaq: BTMD) (“Biote” or the “Company”), a leading innovator advancing the healthspan of patients' lives by providing hormone replacement therapy and…
-
9 months ago benzinga.com
Biote Expects $1.3M Charge For Q4 Due To Recall Of Specific Lots Of Hormone Pellets; Additional Recall Costs In 2026 Estimated At $1.0M
On January 26, 2026, F.H. Investments, Inc. ("Asteria Health"), a 503B manufacturer of compounded bioidentical hormones and wholly-owned subsidiary of biote Corp. (the "Company"), out of an abundance…
10 months ago defenseworld.net
Head to Head Comparison: Agilent Technologies (NYSE:A) vs. biote (NASDAQ:BTMD)
biote (NASDAQ: BTMD - Get Free Report) and Agilent Technologies (NYSE: A - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on…
-
12 months ago benzinga.com
Biote Affirms FY2025 Sales Guidance of $190.000M vs $192.670M Est
Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $190.000 million to $190.000 million vs $192.670 million estimate.
-
12 months ago benzinga.com
Biote Q3 EPS $0.22 Beats $0.07 Estimate, Sales $47.956M Beat $47.757M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.07 by 214.29 percent. This is a 33.33 percent decrease over earnings of $0.33 per…
12 months ago benzinga.com
Earnings Scheduled For November 5, 2025
Earnings Scheduled For November 5, 2025
-
1 year ago benzinga.com
B. Riley Securities Downgrades Biote to Neutral, Lowers Price Target to $4
B. Riley Securities analyst Jeff Van Sinderen downgrades Biote (NASDAQ:BTMD) from Buy to Neutral and lowers the price target from $8 to $4.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Thursday's Pre-Market Session
-
1 year ago benzinga.com
Biote Lowers FY2025 Sales Guidance from $202.000M-$208.000M to $190.000M vs $204.667M Est
Biote (NASDAQ:BTMD) lowers FY2025 sales outlook from $202.000 million-$208.000 million to $190.000 million vs $204.667 million estimate.
-
1 year ago benzinga.com
Biote Q2 EPS $0.10 Beats $0.06 Estimate, Sales $48.90M Miss $49.52M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.06 by 58.73 percent. This is a 152.63 percent increase over losses of $(0.19) per…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
-
1 year ago benzinga.com
Biote Affirms FY2025 Sales Guidance of $202.00M-$208.00M vs $205.31M Est
Biote (NASDAQ:BTMD) affirms FY2025 sales outlook from $202.00 million-$208.00 million to $202.00 million-$208.00 million vs $205.31 million estimate.
-
1 year ago benzinga.com
Biote Q1 EPS $0.37 Beats $0.07 Estimate, Sales $48.99M Beat $46.99M Estimate
Biote (NASDAQ:BTMD) reported quarterly earnings of $0.37 per share which beat the analyst consensus estimate of $0.07 by 428.57 percent. This is a 716.67 percent increase over losses of $(0.06) per…
1 year ago benzinga.com
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Why Meta Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket